舒利迭对COPD稳定期患者临床疗效及IL-8、TNF-α的影响  

Observation of clinical effects of seretide inhalation on COPD in stable phase and its effects on IL-8,TNF-α

作　　者：罗正平[1] 刘仁水[1] 

机构地区：[1]怀化市第二人民医院,湖南怀化418000

出　　处：《现代医药卫生》2010年第11期1614-1615,共2页Journal of Modern Medicine & Health

摘　　要：目的:观察长期吸入舒利迭对慢性阻塞性肺疾病(COPD)稳定期临床疗效及IL-8、TNF-α的影响。方法:对80例COPD稳定期患者,随机分为两组,对照组为常规治疗,治疗组给予常规治疗加用长期吸入舒利迭,观察两组治疗前后的临床疗效、血IL-8、TNF-α进行对比,评价舒利迭对COPD稳定期患者的影响。结果:舒利迭明显缓解COPD临床症状、降低COPD稳定期患者IL-8、TNF-α的表达,与对照组比较差异有显著性。结论:长期吸入舒利迭能缓解患者临床症状、降低IL-8、TNF-α的表达。Objective：To observe the clinical effects of the long-term inhalation of seretide on COPD in stable phase and its effects on IL-8,TNF-α.Methods：80 patients diagnosed as COPD in stable periods,were randomly divided into two groups.The control group was treated with conventional therapy while the treatment group was treated with conventional therapy plus long-term inhalation of seretide.To observe the clinical efficacy,serum IL-8,TNF-α in the two groups before and after treatment.Result：Seretide obviously reliered the clinical sympotms of COPD in stable period,decreased the expression of IL-8,TNF-2.There was significant difference compared with the control group.Conclusion：Long-term inhalation of seretide could alleviate the clinical symptoms and reduce the expression of IL-8,TNF-α in COPD.

关 键 词：舒利迭(氟替卡松/沙美特罗吸入剂) 慢性阻塞性肺疾病 白介素-8 肿瘤坏死因子-Α 

分 类 号：R5[医药卫生—内科学]